AI주식인사이트AI Stock Insight
C

삼양바이오팜

0120G0KOSPI의약품 제조업

48.8 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40
News Sentiment14.3 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samyang Biopharm operates in three main business segments: medical devices, pharmaceuticals, and new drug development. Key products include biodegradable surgical sutures and hemostatic agents in the medical device sector, and anticancer drugs for solid and blood cancers in the pharmaceutical sector. The company is developing gene therapy platforms (SENS) for new drug research, with medical devices contributing 62.5% of total revenue.

Number of Employees

407people

Average Salary

79.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
252.02Industry Average 14.800.0Point

17.0x industry avg (risky)

PBR
2.40Industry Average 1.040.0Point

2.3x industry avg (risky)

ROE
—Industry Average 4.423.5Point
Debt Ratio
1.29Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
2.0 / 4

Detailed News Sentiment

7 totalPositive 3Neutral 1Negative 0Average Sentiment Score 62.5

Detailed Momentum

52-week position5.0Point

52w mid range (40%)

Current 75,800Won52-week high 142,70052-week low 30,200
1-month return0.0Point

1m -17.88% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral기업설명회(IR)개최(안내공시)2026-04-02
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-23
  • Neutral정기주주총회결과2026-03-23
  • Neutral주식등의대량보유상황보고서(일반)2026-03-19